From: Pathogenesis of FUS-associated ALS and FTD: insights from rodent models
Disease | Neuropathology | Genetics | Epidemiology | Clinical features | |
---|---|---|---|---|---|
ALS-FUS | - Degeneration of both upper and lower motor neurons - Significant neuronal loss within anterior horn of spinal cord - Moderate neuronal loss of Betz cells within layer V of motor cortex and motor nuclei of brainstem - Dystrophic neurites, astrogliosis, microglial activation - TDP43-negative, FUS-positive neuronal cytoplasmic inclusions | FUS – over 50 mutations described, particularly missense variations within C-terminal Nuclear Localization Signal | FUS mutations account for ~4 % fALS and ~1 % sALS | - Progressive muscular atrophy - Dysphagia - Dysarthria - Respiratory - Rigid spasticity - Death normally within 2–3 years from symptom onset | |
FTLD-FUS | Atypical FTLD with Ub (aFTLD-U) | - Widespread degeneration of frontal cortex and ventral temporal lobe - Tau/TDP43-negative, FUS-positive neuronal or glial inclusions predominantly within hippocampus, amygdala, frontotemporal cortex and striatum | Rare cases of FUS variants in clinical FTLDÂ (not confirmed pathologically) | ~10Â % FTLD cases display FUS pathology | - Normally behavioural variant FTD - Changes in personality and emotion - Irrationality, compulsiveness, confusion, repetition, inappropriate behaviour - Psychiatric symptoms, depression and anxiety common - Memory, motor function and perception are relatively preserved until late disease stages |
NIFID | - Neuronal cytoplasmic inclusions containing abnormal intermediate filament accumulation | ||||
BIBD | - Significant FUS-pathology plus subcortical basophilic inclusions on H&E staining |